Amgen Played Waiting Game Before Agreeing $3.7bn ChemoCentryx Deal
SEC Filings Show Tactical Negotiations
Amgen’s latest deal shows the biotech major’s need to replenish its portfolios and also the cool heads required when negotiations get heated.
Amgen’s latest deal shows the biotech major’s need to replenish its portfolios and also the cool heads required when negotiations get heated.